Monday, May 4, 2026
← Back to archivePolicy
Policy•Fierce Pharma•May 4, 2026
FDA hands Pfizer, Arvinas’ Veppanu early approval for breast cancer subtype
background ▾
- •Veppanu received FDA accelerated approval, de-risking the ER degrader platform and establishing proof-of-concept for the Pfizer-Arvinas partnership in oncology
- •Pfizer and Arvinas are outsourcing commercialization to an unnamed partner, suggesting they may prioritize this asset for licensing rather than internal sales infrastructure investment
- •Accelerated approval status creates uncertainty around the confirmatory trial pathway and potential label expansion; success or failure will influence the broader ER degrader competitive landscape
PfizerArvinasVeppanu
→ Read original articlePolicy•Fierce Pharma•May 4, 2026
Look out Rexulti, Axsome's Auvelity has its nod for Alzheimer's agitation
background ▾
- •Auvelity is the first FDA-approved treatment specifically designated for agitation associated with Alzheimer's disease, differentiating it from off-label antipsychotic use
- •The approval directly challenges Rexulti's market position, which gained this indication in 2023, creating a competitive dynamic in an underserved patient population
- •Success will depend on payer reimbursement strategy, patient/caregiver awareness, and clinical evidence strength versus Rexulti in head-to-head comparisons
Axsome TherapeuticsOtsukaAuvelityRexultidextromethorphan/bupropion
→ Read original articlePolicy•Fierce Biotech•May 4, 2026
‘Real momentum’ or ‘completely absurd’? How Trump’s support has shaken up psychedelics
background ▾
- •FDA issued priority vouchers for three psychedelic biotech programs (psilocybin-assisted therapy for depression and non-hallucinogenic methylone for PTSD), representing a significant regulatory acceleration for the psychedelic medicine field
- •The executive order's apparent origin in informal conversations with Joe Rogan rather than formal scientific review channels has triggered criticism from medical ethicists and Congressional Democrats regarding FDA institutional independence
- •Watch for: regulatory approval timelines for voucher recipients, Congressional scrutiny of ARPA-H funding allocation, and whether this precedent influences FDA decision-making on other emerging therapies
Compass PathwaysTranscend TherapeuticsUsona Institutepsilocybinmethyloneibogaine
→ Read original articlePolicy•Fierce Pharma•May 4, 2026
FDA expectations create potential friction in new Form 483 response guidance
background ▾
- •FDA issued first-ever draft guidance on Form 483 response best practices, establishing formal expectations for a previously informal process
- •Guidance could create friction between FDA expectations and industry capabilities in responding to inspection observations
- •Industry stakeholders should closely monitor the final guidance and prepare compliance processes accordingly
Policy•STAT News•May 4, 2026
Opinion: STAT+: China’s strict new supply chain regulations could create massive problems for Western biopharma companies
background ▾
- •China's new Decree No. 834 grants sweeping, immediately-enforceable powers to investigate and sanction foreign companies for supply chain decisions, with vague definitions of what constitutes threat to 'industrial chain security' creating substantial legal and commercial uncertainty.
- •China's clinical trial volume exceeded the U.S. in 2020 and reached 5,000+ annually by 2024, with 88% driven by domestic firms—signaling genuine innovation competition rather than outsourcing dependency, fundamentally changing the negotiating landscape.
- •Western pharma must urgently assess China supply chain vulnerabilities, pricing/licensing decisions in China, and R&D footprint exposure to potential government action under this regulation; expect increased IP disputes and access restrictions leveraged as enforcement mechanisms.
Market Access
Market Access•Fierce Biotech•May 1, 2026
‘M&A used to be the only way to go’: Why Seaport’s CEO opted for route to upsized $255M IPO
background ▾
- •Seaport's IPO significantly exceeded guidance ($255M vs. $180M expected), signaling strong investor appetite for independent depression-focused biotech despite recent M&A consolidation trends
- •CEO explicitly positioning company for independent development through Phase 3 for lead program SPT-300 (GlyphAllo) in MDD, leveraging precedent from Intra-Cellular/Caplyta acquisition at $14.5B+ valuation
- •Monitor Phase 2b topline readout for SPT-300 expected in 2025 and funding sufficiency for Phase 3 progression; watch whether independent strategy holds or pivots to M&A if financing tightens
Seaport TherapeuticsBristol Myers SquibbKaruna TherapeuticsSPT-300GlyphAlloSPT-320
→ Read original articleMarket Access•Fierce Biotech•May 4, 2026
Scaling theranostics through access, safety and trust
background ▾
- •Theranostics scaling depends critically on operational infrastructure (ordering, manufacturing, distribution coordination) and stakeholder education, not just clinical efficacy
- •Community oncology adoption requires workforce development, standardized training, and tailored support across multiple disciplines (oncology, nuclear medicine, billing)
Curium
→ Read original articleMarket Access•Fierce Pharma•May 4, 2026
Rising Stars: Axplora’s Arsalan Khan gets technical on marketing
background ▾
Axplora
→ Read original articleMarket Access•Fierce Pharma•May 4, 2026
Cardio drug developer Esperion to go private in potential $1.1B buyout by ArchiMed
background ▾
- •Esperion being acquired by ArchiMed at ~$1.1B valuation reflects investor interest in cardiovascular assets and private equity's appetite for specialty pharma
- •The timing of this acquisition immediately following Esperion's Corstasis/Enbumyst deal suggests ArchiMed sees value in the combined portfolio, particularly the CHF edema indication
- •Monitor ArchiMed's announced development strategy for Enbumyst and other Esperion assets post-close, as private ownership may accelerate or alter commercial timelines
Esperion TherapeuticsArchiMedCorstasis TherapeuticsEnbumyst
→ Read original articleMarket Access•Fierce Pharma•May 4, 2026
Union workers at Korean CDMO Samsung Biologics kick off strike
background ▾
- •Samsung Biologics strike creates potential supply chain risk for clients relying on its CDMO services
- •Duration and scope of work stoppage remain unclear, with impact dependent on strike length and operational mitigation effectiveness
Samsung Biologics
→ Read original articleClinical Trials
Clinical Trials•Fierce Pharma•May 4, 2026
Summit's PD-1xVEGF interim trial miss surprises analysts, shares tumble
background ▾
- •Ivonescimab failed its primary endpoint in the Harmoni-3 interim analysis, marking a critical setback for a leading PD-1xVEGF bispecific in development
- •The trial miss was unexpected by analysts and the market, suggesting the compound may have faced unforeseen efficacy or safety challenges
- •Clarification needed on trial design, specific endpoint data, comparator arms, and Summit's path forward given the ASCO plenary presentation slot
Summit Therapeuticsivonescimab
→ Read original articleClinical Trials•Fierce Pharma•May 4, 2026
A pivotal time for an RNA pioneer
background ▾
- •Ionis has two major Phase 3 readouts pending in lipoprotein(a) and ATTR cardiomyopathy, both backed by major pharma partners (Novartis and AstraZeneca)
- •The company is pursuing a strategic shift toward building its own commercial capabilities rather than remaining purely a platform-focused partner
Ionis PharmaceuticalsNovartisAstraZenecalipoprotein(a) therapeutic (Novartis partnership)ATTR cardiomyopathy therapeutic (AstraZeneca partnership)
→ Read original articleClinical Trials•Fierce Biotech•May 1, 2026
J&J axes $5B CAR-T dream months after touting best-in-disease efficacy
background ▾
- •J&J is terminating JNJ-9530 and JNJ-4496 despite previously reporting best-in-disease efficacy data and enthusiastic R&D leadership commentary, signaling either competitive reassessment or shifting internal priorities away from CAR-T in this indication
- •This removes a competitive threat to Gilead's KITE-363 and KITE-753 programs, which are also in phase 1/2 trials for dual CD19/CD20 targeting
- •Watch for J&J's next moves in CAR-T: whether remaining BCMA program (Carvykti) remains a strategic focus, and whether Gilead gains faster pathway clarity with reduced competition in dual-targeting CAR-T space
Johnson & JohnsonGilead SciencesCellular BiomedicineJNJ-9530JNJ-4496Carvykti
→ Read original articleClinical Trials•Fierce Biotech•May 1, 2026
Genomics inks partnership deal with Greywolf to assess gene datasets
background ▾
- •Greywolf has a Phase 1 study underway in axial spondyloarthritis using ERAP-modulating therapeutics, representing early clinical validation of this target class in autoimmune disease
- •The partnership leverages large-scale genetic datasets to identify disease-associated variants and patient stratification biomarkers, suggesting precision medicine intent for autoimmune indications
Genomics LtdGreywolf Therapeutics
→ Read original articleClinical Trials•Endpoints News•May 1, 2026
Amgen launches late-stage obesity trial in patients who switch from rival drugs
background ▾
- •Amgen is expanding MariTide's late-stage program with three new trials, including a switching study that tests the drug's ability to attract patients from entrenched obesity treatments
- •The switching trial design signals Amgen views MariTide as competitively superior and is building clinical evidence to support market capture in the rapidly growing obesity space
- •Monitor MariTide's Phase 3 efficacy and safety readouts—particularly durability, weight loss magnitude, and adverse event profile versus semaglutide and tirzepatide—as these will determine commercial viability in an increasingly crowded market
AmgenNovo NordiskEli LillyMariTidesemaglutidetirzepatide
→ Read original article